Latest Commercial Milestones News

Cobalt Blue Holdings is pivoting its Broken Hill Technology Centre to process battery black mass, aiming to secure a sustainable domestic feedstock for its Kwinana Cobalt Refinery and unlock near-term revenue opportunities.

Finder Energy is accelerating development of its Kuda Tasi and Jahal fields in Timor-Leste, aiming for first oil by the end of 2027, backed by strong share price momentum and a clear pathway to production.

Terragen Holdings has secured a major purchase order from Mort & Co Fertilisers for its Great Land Plus® bio-stimulant, projecting a significant sales boost in 2026. This deal underscores growing demand for sustainable agricultural solutions.

EBR Systems has achieved a major commercial milestone with Medicare reimbursement approvals for its wireless cardiac pacing WiSE CRT System, driving a 201% revenue increase in Q3 2025. The company is advancing its Limited Market Release as it scales adoption in the US.

Marquee Resources has entered a non-exclusive collaboration with Chinese metallurgical leader Yantai Jinao to advance testwork and commercial pathways for its Mount Clement Antimony Project in Western Australia.

Metal Powder Works has secured a strategic partnership with Hardchrome Engineering, expecting USD 1-2 million in sales over the next year from innovative bronze alloy powders for laser cladding applications.

Skin Elements Limited reports successful completion of key product evaluations and secures $2.5 million placement to fuel growth and commercialisation in 2026.

Argent BioPharma has secured a transformative acquisition of AusCann’s core assets, bolstering its drug delivery technology and manufacturing capabilities ahead of a planned U.S. listing. The company also reported key clinical milestones and refinancing moves in its September 2025 quarterly update.

Premier1 Lithium reports its first inferred gold Mineral Resource at Wadgingarra and a new high-grade gold discovery at Rochefort, alongside a $1.84 million entitlement offer to fund exploration.

EVE Health Group has taken significant strides in commercialising its women’s and men’s health products Dyspro™ and Libbo™, securing regulatory clearances, first patient prescriptions, and raising $1.1 million to support market expansion.

Imugene Limited reports an 81% overall response rate in its azer-cel CAR T-cell therapy trial for difficult lymphomas, alongside a $25 million capital raise that extends its cash runway to mid-2027.

EMVision Medical Devices has successfully closed an oversubscribed Share Purchase Plan, raising $2 million and bringing total recent capital to $14 million. This funding positions the company to advance pivotal clinical trials and regulatory milestones for its innovative neurodiagnostic devices.